Skip to main content
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc — Investor Relations & Filings

Ticker · SNDX ISIN · US87164F1057 LEI · 529900OF94TRHKZVBS87 US Manufacturing
Open in API
Filings indexed 620 across all filing types
Latest filing 2025-02-07 Director's Dealing
Country US United States of America
Listing US SNDX

About Syndax Pharmaceuticals Inc

https://syndax.com/

Syndax Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes therapies for various cancers. The company focuses on developing first-in-class and best-in-class treatments for areas with significant unmet medical needs, such as acute leukemias and chronic Graft-versus-Host Disease (GVHD). Its pipeline targets a range of hematological malignancies and solid tumors, utilizing approaches in epigenetics and immunomodulation to create transformative therapies.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-02-07 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-01-22 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The key content is the announcement of the elimination of the Chief Medical Officer position and the departure of Catherine Madigan, M.D. from that role and the company. This is a change in senior management. The document does not contain financial statements or detailed financial data, nor is it an earnings release or annual report. It specifically relates to management changes, which fits the Board/Management Information category. The document length is 3132 characters, which is typical for an 8-K announcing management changes. Therefore, the appropriate classification is MANG (Board/Management Information).
2024-12-20 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-12-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or other significant information about a company. The text includes an announcement of FDA approval of a drug and a press release attached as an exhibit. There are no detailed financial statements or comprehensive financial data presented. The document is primarily an announcement of a significant event and a press release, not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-11-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or other material information that occurs between periodic reports. The text indicates the announcement of positive topline results from a clinical trial and a press release attached as an exhibit. There is no detailed financial data or comprehensive report content, only a brief event disclosure and reference to a press release. The document length is 4717 characters, which is relatively short and consistent with a current event announcement rather than a full financial report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories like Annual Report or Earnings Release.
2024-11-12 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.